Syros Presents Positive Phase 2 Trial Data Of Tamibarotene Combination: Stock Up In Premarket
Syros Pharmaceuticals (SYRS) announced Wednesday positive initial data from its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute … Read More